Pulse Biosciences, Inc.

We are pleased to share that Prof. Stefano Spiezia will be presenting on nanosecond Pulsed Field Ablation (nano-PFA) technology at the American Thyroid Association conference this week. Join us on October 31 at 9:10a.m. in the Oral Abstracts – Technology & Thyroid room to gain insights into the future of nano-PFA technology. #nanoPFA #pulsebiosciences #minimallyinvasive #ATA2024

Pulse Biosciences will be exhibiting at the American Thyroid Association 2024 conference in Chicago, from October 30th through November 1st. If you would like to learn about Nanosecond Pulsed Field Ablation (nano-PFA) technology and how it is changing minimally invasive procedures, please join us at Booth #506. #nanoPFA #pulsebiosciences #minimallyinvasive #ATA2024

PRESS RELEASE: Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors Link: https://lnkd.in/gQ3d3_kp

PRESS RELEASE: Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System Link: https://lnkd.in/gxRYGfG6

PRESS RELEASE: Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences Link: https://lnkd.in/ghbH4tj8

Press Release: Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation Pulse Biosciences has received Breakthrough Device Designation from the U.S. FDA for our CellFX® nsPFA Cardiac Surgery System for the ablation of cardiac tissue for the treatment of atrial fibrillation (AF). The CellFX nsPFA Cardiac Surgery System with Surgical Clamp, utilizing our proprietary nanosecond Pulsed Field Ablation (nsPFA) technology, is designed to produce durable, continuous transmural ablation lesions during cardiac surgery procedures for the treatment of atrial fibrillation. Based on pre-clinical studies, a single application of less than 2 seconds with the Surgical Clamp creates a consistent, transmural ablation, which is significantly faster, requiring approximately one-twentieth the time of currently available thermal ablation technologies. As Dr. Niv Ad, our Chief Science Officer, Cardiac Surgery, stated, “The theoretical benefits of short-duration, high-amplitude energy pulses with a nonthermal mechanism of action suggest the potential for a safer and more effective treatment.” The Breakthrough Devices Program is a voluntary program for certain medical devices with the potential to provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions, such as atrial fibrillation. Our President and CEO, Burke Barrett added that, “We plan to fully leverage the benefits of this designation and have chosen to seek PMA approval to achieve a specific indication for the treatment of atrial fibrillation. We look forward to aligning with the FDA on a pivotal clinical trial design in the near-term and towards initiating our planned first-in-human cases in the Netherlands soon.” More details about the FDA Breakthrough Designation and additional commentary can be found in the press release: https://lnkd.in/gVttBeZu #PulseBiosciences #CellFX #nsPFA #CardiacSurgery #AtrialFibrillation #BreakthroughTechnology 

We believe safety and efficacy may come down to the nanosecond. Explore the practice-changing potential of our innovative CellFX® Nanosecond Pulsed Field Ablation (nsPFA™) technology and see how we’re advancing our mission to improve care and extend lives: https://lnkd.in/g7zhFZem Indications for Use: The CellFX Percutaneous Electrode System is FDA Cleared for use in the US and intended for ablation of soft tissue in percutaneous, and intraoperative surgical procedures. The CellFX System is also intended for dermatological procedures requiring ablation and resurfacing of the skin. #nsPFA #Ablation #PatientCare #CellFX

Dr. Speizia, we were honored to join you at the MD Anderson Cancer Center's HNS Surgery Research Lecture Series and hear you share your experience with #nsPFA technology. We greatly appreciate your dedication to advancing nsPFA technology, your collaboration and support, and the interest shown by the esteemed doctors at the event. Thank you for representing nsPFA technology and for your continued partnership.

Atrial fibrillation is on the rise, with over 12 million expected annual cases in the US by 2030.¹ Reducing this burden, on patients and healthcare systems alike, requires innovation beyond today’s standards of care. Review the risk factors below and learn how advancements like our CellFX® Nanosecond Pulsed Field Ablation (nsPFA™) technology are designed to offer a potentially safer, more effective solution: https://lnkd.in/gTTxduvQ Caution: Investigational Device. #AtrialFibrillation #nsPFA #PulsedFieldAblation

Thyroid nodules are extremely common and most often benign. But sometimes, they can make speaking, eating, or breathing difficult and may require intervention.¹ If you think you are experiencing symptoms of a thyroid nodule, speak to your doctor today. #ThyroidNodule #Thyroid #SaveYourThyroid